Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brentuximab vedotin - Seagen/Takeda Oncology

X
Drug Profile

Brentuximab vedotin - Seagen/Takeda Oncology

Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; Brentuximab; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seagen; Seattle Genetics; Stanford University; Takeda; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies; Oligopeptides
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Lymphoproliferative disorders; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Primary cutaneous anaplastic large cell lymphoma; Mycosis fungoides
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Hodgkin's disease; Mycosis fungoides; Peripheral T-cell lymphoma; Primary cutaneous anaplastic large cell lymphoma; T-cell lymphoma
  • Phase III Diffuse large B cell lymphoma
  • Phase II Adult T-cell leukaemia-lymphoma; Diffuse scleroderma; Germ cell cancer; Malignant-mesothelioma; Mastocytosis; Non-Hodgkin's lymphoma; Sezary syndrome; Solid tumours
  • Phase I HIV-1 infections
  • No development reported Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Systemic lupus erythematosus

Most Recent Events

  • 31 May 2024 Efficacy and adverse events data from phase III ECHELON-1 trial in Hodgkin's disease presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Adverse events and efficacy data from a phase II trial in Peripheral T-cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top